Lichun Ma

3.4k total citations · 4 hit papers
40 papers, 1.8k citations indexed

About

Lichun Ma is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lichun Ma has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lichun Ma's work include Single-cell and spatial transcriptomics (10 papers), Cancer Genomics and Diagnostics (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Lichun Ma is often cited by papers focused on Single-cell and spatial transcriptomics (10 papers), Cancer Genomics and Diagnostics (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Lichun Ma collaborates with scholars based in United States, China and Hong Kong. Lichun Ma's co-authors include Xin Wei Wang, Tim F. Greten, Jonathan M. Hernandez, Michael C. Kelly, Sean P. Martin, Stephen M. Hewitt, David E. Kleiner, Bradford J. Wood, Bao Tran and Maria O. Hernandez and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lichun Ma

39 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

2019 513 citations Lichun Ma, Maria O. Hernandez et al. Cancer Cell profile →
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

2021 189 citations Lichun Ma, Limin Wang et al. Journal of Hepatology profile →
Biomarkers for immunotherapy of hepatocellular carcinoma

2023 109 citations Tim F. Greten, Firouzeh Korangy et al. profile →
Immunology and immunotherapy of cholangiocarcinoma

2023 102 citations Tim F. Greten, Robert F. Schwabe et al. Nature Reviews Gastroenterology & Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lichun Ma United States	16	787	666	561	460	378	40	1.8k
Davide Ciardiello Italy	22	803 1.0×	1.4k 2.1×	496 0.9×	301 0.7×	496 1.3×	86	2.2k
Giulia Martini Italy	24	793 1.0×	1.4k 2.0×	494 0.9×	243 0.5×	565 1.5×	83	2.1k
Stephen Leong United States	23	842 1.1×	1.1k 1.7×	606 1.1×	178 0.4×	471 1.2×	73	2.3k
Le‐Qun Li China	20	685 0.9×	542 0.8×	598 1.1×	246 0.5×	197 0.5×	63	1.5k
Stefano Caruso France	28	969 1.2×	471 0.7×	687 1.2×	237 0.5×	330 0.9×	55	1.9k
Peter Ansell United States	22	965 1.2×	569 0.9×	675 1.2×	90 0.2×	227 0.6×	89	1.9k
Michael Lahn United States	23	1.3k 1.7×	1.1k 1.7×	400 0.7×	369 0.8×	264 0.7×	42	2.2k
Kaoru Mogushi Japan	29	1.6k 2.1×	756 1.1×	799 1.4×	203 0.4×	491 1.3×	93	2.7k
Ming-Hui Dong China	11	1.1k 1.4×	1.4k 2.1×	528 0.9×	1.4k 3.0×	376 1.0×	16	2.6k
Tingbo Liang China	24	915 1.2×	696 1.0×	454 0.8×	251 0.5×	402 1.1×	86	2.2k

Countries citing papers authored by Lichun Ma

Since Specialization

Citations

This map shows the geographic impact of Lichun Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lichun Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lichun Ma more than expected).

Fields of papers citing papers by Lichun Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lichun Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lichun Ma. The network helps show where Lichun Ma may publish in the future.

Co-authorship network of co-authors of Lichun Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Lichun Ma. A scholar is included among the top collaborators of Lichun Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lichun Ma. Lichun Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Lichun, et al.. (2024). Higher education investment, human capital, and high-quality economic development. Finance research letters. 71. 106419–106419. 7 indexed citations

Tian, Cheng, Wentao Yang, Xiaoli Liu, et al.. (2024). HKDC1 promotes liver cancer stemness under hypoxia through stabilizing β-catenin. Hepatology. 81(6). 1685–1699. 8 indexed citations

Robinson, Welles, Joshua K. Stone, Fiorella Schischlik, et al.. (2024). Identification of intracellular bacteria from multiple single-cell RNA-seq platforms using CSI-Microbes. Science Advances. 10(27). eadj7402–eadj7402. 10 indexed citations

Qin, Shulin, Lichun Ma, Runfeng Li, et al.. (2023). Multifunctional Ca2+ nanomodulators regulate type I interferon pathway to remodel tumor microenvironment for cancer immunotherapy. Chemical Engineering Journal. 477. 147118–147118. 5 indexed citations

Kedei, Noémi, Subreen A. Khatib, Marshonna Forgues, et al.. (2023). Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatology. 79(4). 768–779. 11 indexed citations

Green, Benjamin L., Yuta Myojin, Chi Ma, et al.. (2023). Immunosuppressive CD29 ⁺ Treg accumulation in the liver in mice on checkpoint inhibitor therapy. Gut. 73(3). 509–520. 7 indexed citations

Wen, Yankai, Lichun Ma, & Cynthia Ju. (2023). Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases. SHILAP Revista de lepidopterología. 1(2). e100020–e100020. 9 indexed citations

Greten, Tim F., Robert F. Schwabe, Nabeel Bardeesy, et al.. (2023). Immunology and immunotherapy of cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology. 20(6). 349–365. 102 indexed citations breakdown →

Khatib, Subreen A., Lichun Ma, Hien Dang, et al.. (2022). Single‐cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in HCC. Hepatology. 76(3). 599–611. 14 indexed citations

10.

Monge, Cecilia, Erica C. Pehrsson, Changqing Xie, et al.. (2022). A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. The Oncologist. 27(3). e273–e285. 32 indexed citations

11.

Chang, Ching-Wen, Wei Zhuang, Stewart R. Durell, et al.. (2022). A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy. iScience. 25(10). 105244–105244. 4 indexed citations

12.

Ma, Lichun & Xin Wei Wang. (2022). Dissecting liver tumor heterogeneity to improve health equity. Trends in cancer. 8(4). 286–290. 3 indexed citations

13.

Hung, Man‐Hsin, Joo Sang Lee, Chi Ma, et al.. (2021). Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nature Communications. 12(1). 1455–1455. 163 indexed citations

14.

Liu, Yuchen, Shu Zhuo, Yaxing Zhou, et al.. (2021). Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. Journal of Hepatology. 76(3). 652–664. 66 indexed citations

15.

Zhao, Na, Hien Dang, Lichun Ma, et al.. (2020). Intratumoral γδ T‐Cell Infiltrates, Chemokine (C‐C Motif) Ligand 4/Chemokine (C‐C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma. Hepatology. 73(3). 1045–1060. 53 indexed citations

16.

Martin, Sean P., Valerie Fako, Hien Dang, et al.. (2020). PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 39(1). 99–99. 75 indexed citations

17.

Heinrich, S., Amanda J. Craig, Lichun Ma, et al.. (2020). Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology. 74(3). 700–715. 64 indexed citations

18.

Ma, Lichun, Maria O. Hernandez, Yongmei Zhao, et al.. (2019). Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell. 36(4). 418–430.e6. 513 indexed citations breakdown →

19.

Zou, Bin, Victor Lee, Lijiang Chen, et al.. (2017). Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Scientific Reports. 7(1). 6595–6595. 31 indexed citations

20.

Wang, Debby D., Victor Lee, Guangyu Zhu, et al.. (2016). Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. Molecular BioSystems. 12(5). 1552–1563. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact